伊立替康/奥沙利铂联合卡培他滨治疗晚期结肠癌的疗效比较

Comparison of Irinotecan/Oxaliplatin Combined with Capeci Tabine in the Treatment of Advanced Colorectal Cancer Treatment

目的对分别选择伊立替康+卡培他滨以及奥沙利铂+卡培他滨两种方法对晚期结肠癌患者进行治疗后获得的临床效果进行探讨。方法方便选择该院2011年4月—2016年4月晚期结肠癌患者62例作为此次实验研究对象,通过随机数表法展开分组;临床采用伊立替康+卡培他滨对观察组31例患者进行治疗,临床采用奥沙利铂+卡培他滨对对照组31例患者进行治疗;对比两组患者的近期疗效及完成化疗后出现的不良反应。结果观察组患者的近期疗效为74.19%、对照组为70.97%,两组差异无统计学意义(P>0.05);观察组出现不良反应的概率为19.35%、对照组为22.58%,两组患者差异无统计学意义(P>0.05)。结论对于晚期结肠癌患者,临床治疗药物选择伊立替康+卡培他滨或者选择奥沙利铂+卡培他滨,均可以获得显著的治疗效果,出现肠道、周围神经毒性等不良反应,需认真观察。

Objective To choose the set respectively for kang plus capecitabine and oxaliplatin into plus capecitabine two methods for treating patients with advanced colon cancer clinical effect were discussed. Methods Convenient chose the hos-pital from April 2011 to April 2016, 62 cases of patients with colon cancer as the research object, the trial group through random indicator method;For clinical using, vertical kang plus capecitabine treatment for 31 cases in the observation group, the clinical use plus oxaliplatin into capecitabine control group of 31 cases of patients for treatment; Comparison of two groups of patients in the near future curative effect and adverse reaction after chemotherapy. Results Observation group of patients with a recent curative effect was 74.19%, the control group was 70.97%, the difference between the two groups had no statistical significance（P〉 0.05）; Observation group appears the probability of adverse reactions was 19.35%, the control group was 22.58%, there was no statistically significant difference in both groups（P〉 0.05）. Conclusion For patients with advanced colon cancer, clinical drug selection, stand for, plus capecitabine or select plus capecitabine and oxaliplatin into, can obtain obvious therapeutic effect, adverse reactions such as intestinal, peripheral nerve toxicity, need to carefully ob-serve, corresponding solving measures.